PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.21%
R&D reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive implications.
-6.73%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
55.79%
Other expenses change of 55.79% versus flat Biotechnology costs. Walter Schloss would verify efficiency.
-5.86%
Operating expenses reduction while Biotechnology median is 5.50%. Seth Klarman would investigate advantages.
-5.86%
Total costs reduction while Biotechnology median is 5.38%. Seth Klarman would investigate advantages.
-72.88%
Interest expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
55.79%
D&A change of 55.79% versus flat Biotechnology D&A. Walter Schloss would verify adequacy.
-143.43%
EBITDA decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
5.86%
Operating income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
-101.24%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-142.73%
Pre-tax income decline while Biotechnology median is -0.79%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-72.88%
Tax expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-142.73%
Net income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-120.58%
EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
-120.58%
Diluted EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
10.21%
Share count reduction below 50% of Biotechnology median of 0.11%. Jim Chanos would check for issues.
10.21%
Diluted share reduction below 50% of Biotechnology median of 0.11%. Jim Chanos would check for issues.